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Efficacy of systemic temozolomide-activated
phage-targeted gene therapy in human glioblastoma
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Abstract
Glioblastoma multiforme (GBM) is the most lethal primary intracra-
nial malignant neoplasm in adults and most resistant to treatment.
Integration of gene therapy and chemotherapy, chemovirotherapy,
has the potential to improve treatment. We have introduced an
intravenous bacteriophage (phage) vector for dual targeting of ther-
apeutic genes to glioblastoma. It is a hybrid AAV/phage, AAVP,
designed to deliver a recombinant adeno-associated virus genome
(rAAV) by the capsid of M13 phage. In this vector, dual tumor target-
ing is first achieved by phage capsid display of the RGD4C ligand
that binds the avb3 integrin receptor. Second, genes are expressed
from a tumor-activated and temozolomide (TMZ)-induced promoter
of the glucose-regulated protein, Grp78. Here, we investigated
systemic combination therapy using TMZ and targeted suicide gene
therapy by the RGD4C/AAVP-Grp78. Firstly, in vitro we showed that
TMZ increases endogenous Grp78 gene expression and boosts trans-
gene expression from the RGD4C/AAVP-Grp78 in human GBM cells.
Next, RGD4C/AAVP-Grp78 targets intracranial tumors in mice
following intravenous administration. Finally, combination of TMZ
and RGD4C/AAVP-Grp78 targeted gene therapy exerts a synergistic
effect to suppress growth of orthotopic glioblastoma.
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Introduction
Glioblastoma, also known as glioblastoma multiforme (GBM) or
grade IV astrocytoma, is the most common and deadliest of primary
brain tumors in adults with 14.6-month median survival time and a
2% 5-year survival rate (Kwiatkowska et al, 2013). This depressing
prognosis occurs with current, aggressive gold standard treatment
regimens, such as chemotherapy. Even more recent trials with anti-
angiogenic and molecularly targeted therapies have shown only
slight improvements in GBM outcome (Gilbert et al, 2014). There-
fore, novel remedies that effectively treat or improve/complement
existing treatments are pressingly needed. Temozolomide (TMZ), an
alkylating agent able to cross the blood–brain barrier (BBB), is well-
tolerated and widely used as part of standard chemotherapy for
newly diagnosed and recurrent GBM, but has limited efficacy (Thon
et al, 2013; Messaoudi et al, 2015; Taal et al, 2015). We hypothe-
sized that combining TMZ chemotherapy with gene therapy should
yield a synergistic effect against GBM. Gene therapy for GBM has
been attempted for the past 24 years, but progress has been
hindered mostly by lack of tumor selectivity and inefficiency of
eukaryotic viral vectors (Natsume & Yoshida, 2008; Kwiatkowska
et al, 2013). Gene therapy of brain tumors is further hampered by
the BBB (Maguire et al, 2014). Although this could be circumvented
by delivery of vectors locally, the invasiveness of repeated intracere-
bral injections and the diffuse/not discrete nature of GBM place
great limitations. We have introduced a unique prokaryotic viral-
based approach of systemic intravenous gene delivery to target
tumors specifically by using the harmless and non-pathogenic fila-
mentous M13 bacteriophage, a virus that infects only bacterial cells
and lacks native tropism to normal tissues in human and eukaryotes
in general (Asavarut & Hajitou, 2014). A key strategy of our
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systemic delivery platform involves the construction of a hybrid
bacteriophage vector termed AAV-phage, or AAVP (Fig EV1A). In
this vector, the single-stranded genome of human adeno-associated
virus (AAV) was inserted within the M13 phage single-stranded
genome, resulting in a phage capsid which incorporates AAV
genomes(s) (Hajitou et al, 2006, 2007). Importantly, the phage
capsid was engineered to display the CDCRGDCFC (RGD4C) ligand
(Fig EV1A) that binds the heterodimer avb3 integrin cell surface
receptor, which is overexpressed on tumor cells and supporting
angiogenic vasculature in most tumor types including human GBM
(Hajitou et al, 2006; Schnell et al, 2008). Upon binding to avb3 inte-
grin receptor and subsequent entry of the RGD4C/AAVP viral parti-
cles into cells, the AAV genome is released to express genes in
tumors from a cytomegalovirus, CMV, promoter (Hajitou et al,
2006). To date, we and collaborators have established that these
vectors target various preclinical models of human cancer including
soft tissue sarcoma, melanoma, breast, prostate, and pancreatic
cancers (Hajitou et al, 2006, 2008; Tandle et al, 2009; Yuan et al,
2013; Dobroff et al, 2016; Smith et al, 2016). Additionally, a study
by the National Cancer Institute, USA, using our vector in pet dogs
with natural cancers demonstrated that RGD4C/AAVP delivered the
cytokine, tumor necrosis factor-alpha (TNFa), selectively, to sponta-
neous cancers (Paoloni et al, 2009). Remarkably, repeated vector
dosing proved safe and resulted in complete tumor eradication in
several dogs with aggressive cancers (Paoloni et al, 2009). To
improve the vector platform for use in targeted gene therapy against
GBM, we have refined the technology by replacing the CMV
promoter with the tumor-specific Grp78 promoter and designed the
dual tumor targeting RGD4C/AAVP-Grp78 vector (Kia et al, 2012,
2013). This novel vector effectively ensured further tumor selectiv-
ity, through transcriptional targeting as previously reported (Kia
et al, 2012). We also demonstrated that the RGD4C/AAVP-Grp78
vector provides much longer lasting transgene expression than the
RGD4C/AAVP-CMV vector carrying a CMV promoter, in vitro and
in vivo in subcutaneous GBM following intravenous administration
(Kia et al, 2012). The Grp78 promoter is marginally active in healthy
tissues; however, potent activation has been observed in aggressive
tumors, including GBM (Dong et al, 2004; Pyrko et al, 2007; Virrey
et al, 2008), and is induced by stress and conditions of tumor
microenvironment such as glucose deprivation, chronic anoxia, and
acidic pH. It is further worth considering that the induction of the
Grp78 gene expression and activation confers drug resistance in a
variety of human tumors, including gliomas (Li & Lee, 2006; Lee,
2007; Pyrko et al, 2007). Grp78 can also be induced by TMZ in GBM
(Pyrko et al, 2007), and its activation has been associated with GBM
resistance to TMZ (Pyrko et al, 2007; Virrey et al, 2008). Thus,
further increase in gene expression from the RGD4C/AAVP-Grp78
can be ensured through TMZ activation of the Grp78 promoter.
Consequently, we postulated that RGD4C/AAVP-Grp78 is a suitable
candidate for use in combination with TMZ against GBM. Herein,
we investigated the effects of combining TMZ chemotherapy and
targeted gene therapy with RGD4C/AAVP-Grp78, termed chemovi-
rotherapy, against intracranial orthotopic models of human glioblas-
toma. Firstly, we demonstrated that a list of various human
glioblastoma cell lines as well as primary GBM and primary GBM
stem cells express avb3 integrin, a receptor of RGD4C, resulting in
ligand-directed gene delivery by RGD4C/AAVP in vitro. Then, we
showed that TMZ treatment of human glioblastoma cell lines
increased expression of the endogenous Grp78, through the UPR
(unfolded protein response) pathway, subsequently stimulating
RGD4C/AAVP-Grp78-mediated gene expression. We also found that
TMZ amplified the destruction of GBM cells in combination with
RGD4C/AAVP-Grp78-HSVtk encoding the Herpes simplex virus type I
thymidine kinase in the presence of ganciclovir (GCV); we used the
HSVtk mutant SR39 (Black et al, 2001). Next, we confirmed that
RGD4C/AAVP-Grp78 targets orthotopic glioblastoma in mice after
intravenous administration selectively binding to tumor cells and
tumor vasculature without accumulation in the healthy brains.
Additionally, the combination of TMZ and RGD4C/AAVP-Grp78-
HSVtk/GCV administered systemically elicited strong anti-tumor
activity against intracranial glioblastoma established in vivo from
GBM cell lines and primary GBM, and in both immunodeficient and
immunocompetent mice. Unless technically, the in vivo effect was
measured synergistic, compared to TMZ or RGD4C/AAVP-Grp78-
HSVtk/GCV alone. The HSVtk enzyme phosphorylates prodrug
nucleoside analogues such as GCV and converts them into nucle-
oside analogue triphosphates. These triphosphate GCV compounds
are then incorporated into the cellular genome, inhibit DNA poly-
merase, and subsequently induce cell death by apoptosis (Hamel
et al, 1996; Natsume & Yoshida, 2008). It is important to note that
the HSVtk/GCV approach also elicits a bystander effect, which
means that cells containing the HSVtk kill neighboring non-trans-
duced cells through the gap junctional intercellular communications
(GJIC) that allow the transfer of the converted cytotoxic drug and/
or toxic metabolites between these cells as we have previously
reported (Trepel et al, 2009; Duarte et al, 2012). After a few days,
“this bystander effect” results in increased cell killing by the
RGD4C/AAVP-HSVtk vector and may potentially overcome the
requirement for all malignant cells to be transduced in order to
achieve meaningful tumor regression. Altogether, these findings
indicate that this combination therapy strategy offers significant
translational potential in the treatment regime for GBM patients.
Results
Human glioblastoma cell lines express integrin receptors
of RGD4C and are subsequently transduced by the
RGD4C/AAVP vector
As initial experiments, we conducted in vitro studies on cell lines by
using three models of human glioblastoma cells, namely LN229,
U87, and SNB19, considered as common cellular models of this
disease. First, we investigated expression of the integrins avb3 and
avb5, receptors for RGD4C/AAVP, by immunofluorescent staining of
aV, b3, and b5 integrin subunits. As shown in Fig 1A, all tumor cells
tested were positive for expression of av, b3, and b5 integrins, with
varying expression of each integrin. Next, we investigated RGD4C/
AAVP-mediated gene delivery to these tumor cells and used vectors
carrying the reporter Luciferase (Luc) gene, which allows quantita-
tive analysis of gene expression, and analyzed Luc expression over
time. Cells were incubated with targeted RGD4C/AAVP-Luc or
control non-targeted/AAVP-Luc vector (lacking the RGD4C).
RGD4C/AAVP-mediated gene expression was demonstrated in all
the human glioblastoma cells tested, in an efficient way and which
increased over time (Fig 1B). Importantly, gene expression
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mediated by RGD4C/AAVP was selective, targeted, and dependent
on RGD4C ligand binding to integrin receptors as no Luc expression
was detected in cells treated with the control non-targeted/AAVP-
Luc (Fig 1B).
Temozolomide treatment of human glioblastoma cells results in
induction of the endogenous Grp78 gene and boosts gene
expression from the RGD4C/AAVP-Grp78
Numerous studies have reported that treatment with chemothera-
peutic drugs stimulates endogenous Grp78 gene expression in
tumors (Pyrko et al, 2007). It has also been reported that treat-
ment with TMZ induces expression of endogenous Grp78 in
glioblastoma patients, which is associated with glioblastoma resis-
tance to TMZ (Virrey et al, 2008). Thus, we examined whether
TMZ can increase the Grp78 promoter activity in the context of
RGD4C/AAVP-Grp78 vector in vitro and subsequently enhance
gene expression. First, we sought to confirm that TMZ activates
expression of the endogenous Grp78 gene in glioblastoma cell
lines. The LN229, U87, and SNB19 cells were treated with a
range of TMZ concentrations (25–250 lM) for 12 h, followed by
Western blot analysis and band intensity quantification. As shown
in Fig 1C, the expression of endogenous Grp78 increased in a
dose-dependent manner in LN229, U87, and SNB19 cells. We also
noted that Grp78 expression in SNB19 reached a plateau between
100 and 250 lM of TMZ.
We next set out to determine the effect of TMZ on transgene
expression mediated by the RGD4C/AAVP-Grp78 in human glioblas-
toma cells. Vectors carrying the Luc reporter gene were utilized, and
stably transduced LN229, U87, and SNB19 cells were generated by
using puro vectors that confer resistance to puromycin. Vectors
expressing the Luc gene from the CMV promoter (RGD4C/AAVP-
CMV-Luc) were also included in this experiment. Based on our data
in Fig 1C, we used TMZ concentrations of 100 lM for LN229 and
SNB19, and 60 lM for U87. Remarkably, TMZ induced a sharp
increase in Luc expression in all LN229, U87, and SNB19 glioblas-
toma cells in which the Luc transgene was mediated by the RGD4C/
AAVP-Grp78-Luc (Fig 1D). In contrast, Luc expression driven by the
RGD4C/AAVP-CMV-Luc remained unaltered by TMZ in all tumor
cells (Fig 1D). In LN229 and U87 cells, the rise in Luc expression
occurred at 9 h post-TMZ treatment and continued gradually to
reach 20- and 15-fold higher than RGD4C/AAVP-CMV-Luc at 12 h,
respectively (Fig 1D). In the SNB19 cell line, the boost in Luc
expression occurred at 24 h post-TMZ treatment and reached ~ 4.3-
fold increase (Fig 1D).
To further investigate induction of the RGD4C/AAVP-Grp78
vector in human glioma by other anti-cancer agents, known for
their ability to cross the BBB, we treated human glioma cells with
increasing concentrations of curcumin (0–40 lM). Curcumin, a
natural and non-toxic dietary plant-based product, has been high-
lighted for its potential as an anti-cancer agent, due to its ability
to induce tumor cell death with no systemic side effects. Studies
have shown that curcumin can prevent proliferation of cancer
cells including GBM (Klinger & Mittal, 2016). Addition of
curcumin to tumor cells at day 3 post-transduction with RGD4C/
AAVP-Grp78-Luc vector resulted in a dose-dependent increase of
Luc gene expression that climbed markedly in the presence of
40 lM of curcumin (Fig EV1B).
Temozolomide induces Grp78 promoter activation through the
UPR signaling pathway
To investigate whether the boost of RGD4C/AAVP-Grp78 gene
expression by TMZ is mediated through the conserved signaling
cascade termed UPR (unfolded protein response) pathway that regu-
lates the endogenous Grp78 gene, we examined three transmem-
brane proteins representing the three arms of the UPR signaling
pathway (Rutkowski & Kaufman, 2004; Pfaffenbach & Lee, 2011;
Luo & Lee, 2013; Nagelkerke et al, 2014). These experiments were
performed following TMZ treatment of LN229, U87, and SNB19
tumor cells stably transduced with the RGD4C/AAVP-Grp78-Luc
vector, consistent with the experiments in Fig 1. We first focused on
protein kinase RNA-like ER kinase (PERK); after homo-dimerization
and trans-autophosphorylation, PERK phosphorylates Ser51 of the
a-subunit of the eukaryotic translation initiation factor-2 (eIF2a;
Luo & Lee, 2013; Ron & Walter, 2007) that selectively promotes
translation of the transcription factor ATF4 which induces the Grp78
promoter. Western blot analyses of tumor cells showed that TMZ
induces expression of the phospho-eIF2a that is detectable at 2, 1,
and 3 h post-TMZ treatment in LN229, U87, and SNB19 cells,
respectively, and induction of expression persisted for up to 24 h
post-TMZ treatment (Fig 2A). Next, we evaluated TMZ induction of
expression of the activating transcription factor 6 (ATF6). We found
that TMZ induces the ATF6-p90 expression detectable at 1 h in
LN229 and 2 h in U87 cells, and then increased over time for 24 h
post-treatment (Fig 2A). The induction of ATF6-p90 in SNB19 cells
was noticed 24 h after TMZ treatment (Fig 2A). Previous studies
have shown that an increase in the 90-kDa ATF6 level indicates
initiation of the endoplasmic reticulum (ER) stress pathway and
subsequently activation of UPR (Teske et al, 2011; Kia et al, 2012),
which is a cellular stress response related to the ER stress. Finally,
during ER stress, activated inositol-requiring enzyme 1 (IRE1)
cleaves a 26-base intron from mRNA of X-box binding protein 1
(XBP1) resulting in a product that acts as a transcription factor for
the Grp78 promoter (Teske et al, 2011). Semi-quantitative RT–PCR
analyses showed a slight increase in spliced XBP1 mRNA at 24 h
post-TMZ treatment of LN229 (Fig 2B), while a greater and gradual
increase in the level of spliced XBP1 mRNA was found in the U87
cell line upon TMZ treatment (Fig 2B). In contrast, no spliced XBP1
mRNA was detected in SNB19 glioblastoma cells (Fig 2B).
Combination of TMZ with RGD4C/AAVP-Grp78-HSVtk and GCV
produces strong tumor cell killing in vitro
Our previous studies showed that the RGD4C/AAVP-Grp78-HSVtk is
superior to the conventional RGD4C/AAVP-CMV-HSVtk vector in
inducing glioblastoma cell killing in vitro as well as GBM growth
inhibition in vivo following intravenous administration of vectors
carrying the HSVtk, and intraperitoneal injection of GCV (Kia et al,
2012). Herein, we compared tumor cell killing between two combi-
nations of TMZ with RGD4C/AAVP-Grp78-HSVtk/GCV and TMZ
with RGD4C/AAVP-CMV-HSVtk/GCV. We also included a compre-
hensive list of controls comprising cells treated with monotherapies
of TMZ, RGD4C/AAVP-Grp78-HSVtk or RGD4C/AAVP-CMV-HSVtk
vectors alone plus GCV, in addition to untreated cells. Cells stably
transduced with RGD4C/AAVP-Grp78-HSVtk or RGD4C/AAVP-CMV-
HSVtk were subjected to GCV or TMZ, or both for 4 days before
ª 2019 The Authors EMBO Molecular Medicine 11: e8492 | 2019 3 of 21
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evaluation of the reactive oxygen species (ROS). Excessive production
of ROS causes progressive oxidative damage and ultimately cell
death. The current experiments have yielded numerous new findings.
Firstly, both RGD4C/AAVP-Grp78-HSVtk and RGD4C/AAVP-CMV-
HSVtk vectors showed cell killing in combination with GCV in all
tumor cells (Fig 2C). However, the RGD4C/AAVP-Grp78-HSVtk
generated greater glioblastoma cell killing, in general, than the
RGD4C/AAVP-CMV-HSVtk (Fig 2C), which confirms our previous
findings (Kia et al, 2012). Secondly, combination of RGD4C/AAVP/
GCV with TMZ significantly decreased proliferation of all LN229,
U87, and SNB19 glioblastoma cells, when compared to each RGD4C/
AAVP/GCV or TMZ therapy alone (Fig 2C). Finally, importantly, cells
treated with the combination of RGD4C/AAVP-Grp78-HSVtk/GCV
and TMZ demonstrated significant increase in cell death compared to
cells treated with combination of RGD4C/AAVP-CMV-HSVtk/GCV
and TMZ (Fig 2C). Given these data and those on TMZ induction of
gene delivery by RGD4C/AAVP-Grp78-Luc vector, we selected
RGD4C/AAVP-Grp78-HSVtk/GCV as most suitable for in vivo studies
and therapy combination with TMZ against orthotopic GBM.
RGD4C/AAVP-Grp78-HSVtk vector targets intracranial human
glioblastoma in vivo following intravenous administration
These in vivo experiments were performed before initiating therapy
studies in order to determine the ability of RGD4C/AAVP-Grp78-
HSVtk vector to target an orthotopic model of human GBM in vivo
following intravenous administration. As a preclinical model, we
used brain tumors established in immunodeficient nude mice by
intracranial implantation of U87 glioblastoma cells stably labeled
with the firefly Luc transgene. Bioluminescent imaging (BLI) of Luc
expression in tumors was used for tumor detection and for monitor-
ing tumor growth. When tumors were established as revealed by
BLI of Luc, we systemically (tail vein) administered RGD4C/AAVP-
Grp78-HSVtk or control non-targeted/AAVP-Grp78-HSVtk (5 × 1010
transducing units (TU)/mouse). At 18 h after vector administration,
tumor-bearing nude mice were killed, and then, tumors and control
organs were collected. Immunofluorescence staining of frozen brain
sections showed strong expression of av integrin in the tumors but
not in the surrounding healthy brain (Fig 3A). Then, immunostain-
ing of phage particles revealed distribution of the tumor-targeted
RGD4C/AAVP-Grp78-HSVtk (green) throughout the tumor in the
blood vessels (CD31—red) and surrounding cells (Fig 3B). No signal
was detected in the surrounding healthy brain (Fig 3B).
Additionally, relative targeted RGD4C/AAVP-Grp78-HSVtk
homing was quantified by recovery from tissue homogenates, bacte-
rial infection, and counting the TU. We observed marked enrich-
ment of RGD4C/AAVP-Grp78-HSVtk particles in orthotopic U87
xenografts (Fig 3C). Specifically, we found a ~ 12-fold enrichment
compared with homing of non-targeted/AAVP-Grp78-HSVtk control
to size-matched tumors and to control organs (Fig 3C). Further-
more, only background levels of RGD4C/AAVP-Grp78-HSVtk were
observed in normal brains and control tissues, i.e., pancreas
(Fig 3C). These data establish that RGD4C/AAVP-Grp78-HSVtk
targets U87 orthotopic xenografts in nude mice upon intravenous
administration. Moreover, further analyses of the vector tumor
homing showed that we recovered an estimate of ~ 7 × 106 TU/g
tumor tissue of intact RGD4C/AAVP particles following intravenous
administration of a fixed vector dose of 5 × 1010 TU/mouse. This
does not take into account the non-infectious vector that has initi-
ated processing by the cells (Fig 3D).
Systemic chemovirotherapy combining RGD4C/AAVP-Grp78-
HSVtk/GCV suicide gene therapy with TMZ enhances human
glioblastoma destruction in vivo
Next, we evaluated therapeutic efficacy of the systemic chemovi-
rotherapy in vivo against intracranial tumors, established by
implantation of U87 cells labeled with the Luc reporter gene, and
Luc expression in tumors was monitored by repetitive BLI of
whole living tumor-bearing mice. We selected BLI of Luc expres-
sion as a simple way to monitor tumor viability and response to
treatments (Hajitou et al, 2006, 2007, 2008; Kia et al, 2012; Przys-
tal et al, 2013). At day 9 post-tumor cell implantation, mice with
established intracranial U87 tumors (Fig 4A) received a single
intravenous dose (5 × 1010 TU) of either targeted RGD4C/AAVP-
Grp78-HSVtk or non-targeted/AAVP-Grp78-HSVtk. To optimize the
model in the context of in vivo expression, TMZ was adminis-
tered 4 days after intravenous vector delivery, as most of our
previous studies (Hajitou et al, 2006, 2007; Kia et al, 2012; Przys-
tal et al, 2013) have shown that initiation of RGD4C/AAVP-
mediated gene expression in tumors occurs after day 4 following
vector injection, at which time point the administered TMZ is
able to boost Grp78 promoter activity and subsequent gene
expression. Furthermore, giving TMZ before initiation of gene
expression could affect the intracellular trafficking of RGD4C/
AAVP-Grp78-HSVtk and subsequent tumor cell transduction,
◀ Figure 1. Targeted transduction of human glioblastoma cell lines and induction of RGD4C/AAVP-Grp78 by TMZ.A Immunofluorescence staining of LN229, U87, and SNB19 tumor cells with primary antibodies against av, b3 or b5 integrin subunits. Scale bars, 20 lm for LN229 and
SNB19, and 50 lm for U87.
B Targeted gene delivery into LN229, U87, and SNB19 cells by RGD4C/AAVP-Luc carrying the Luc reporter gene. Cells were seeded into 48-well plates before
transduction. Non-targeted/AAVP-Luc was used as negative control for targeted transduction. Results represent the average relative luminescence units (RLU)/1 lg
protein. Data shown are representative of two experiments, n = 3.
C Western blot analysis of the endogenous Grp78 protein expression levels in LN229, U87, and SNB19 cells following treatment with increasing concentrations of TMZ.
Grp78 level was normalized to GAPDH. Data shown in right panel are representative of two experiments, n = 3.
D Induction of Grp78 promoter activity by TMZ in RGD4C/AAVP-Grp78-Luc cells. LN229, U87, and SNB19 cells stably transduced with RGD4C/AAVP-Grp78-Luc or RGD4C/
AAVP-CMV-Luc were grown in the presence of TMZ for the indicated times. Results represent the average RLU/1 lg protein. Data shown are representative of two
experiments, n = 3. Two-way ANOVA with Bonferroni correction (GraphPad Prism 6) was used for data analysis.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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before even enough vector genome has reached the nucleus to
initiate gene expression. Therefore, daily doses of intraperitoneal
GCV and/or TMZ treatments started at day 13 post-tumor cell
implantation and lasted for 6 days.
At day 27, post-cell implantation, Luc expression within the U87
tumors increased rapidly in groups of mice administered with the
control non-targeted/AAVP-Grp78-HSVtk vector and GCV (Fig 4A).
In contrast, although we observed an increase in Luc expression in
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Figure 2. TMZ activation of the UPR pathway and subsequent enhancement of glioblastoma cell killing in vitro by the RGD4C/AAVP-Grp78-HSVtk
and GCV.
A TMZ induction of phospho-eIF2a and ATF6-p90 expression. Human glioblastoma cells transduced with RGD4C/AAVP-Grp78 were analyzed by Western blot following
treatment with TMZ (100 lM for LN229 and SNB19, 60 lM for U87). GAPDH was used as a control.
B RT–PCR analysis of constitutive expression and splicing of XBP1 in glioblastoma cells transduced with RGD4C/AAVP-Grp78, in the presence of TMZ. Sizes of the PCR
products were 289 bp for unspliced XBP1 and 263 bp for spliced XBP1, and the lower size band is not specific. Time points were selected among those tested in the
Western blot in (A), subsequently the image containing 0, 1, and 2 h was juxtaposed to images of 6, 12, and 24 h. A white line has been added between the gel pieces
that have been juxtaposed.
C Tumor cell killing in vitro by the HSVtk/GCV approach. Glioblastoma cells stably transduced with RGD4C/AAVP-Grp78-HSVtk or RGD4C/AAVP-CMV-HSVtk were treated
with either GCV (10 lM) or TMZ (100 lM for LN229 and SNB19, 60 lM for U87) or combination of both GCV and TMZ. Cells were stained with MitoSOX and analyzed
by FACS at day 4 post-treatment. Data shown are representative of three experiments, n = 3. Two-way ANOVA with Tukey’s multiple comparison test (GraphPad
Prism 6) was used for data analysis.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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Figure 3. Systemic targeting of orthotopic glioblastoma with RGD4C/AAVP-Grp78-HSVtk.
A Immunofluorescent staining for av integrin expression in brain sections including intracranial tumor (T) and the surrounding healthy brain (B). Scale bar, 100 lm.
B Co-staining of CD31 (red) and phage (green) in brain sections comprising tumor and healthy brain. Scale bar, 100 lm. A high-magnification view from the low-
magnification insert of the tumor section is shown. Scale bar, 25 lm.
C Quantification of the relative homing ability of RGD4C/AAVP-Grp78-HSVtk to brain tumors, brain tissue, and pancreas after intravenous administration. The data were
normalized both to non-targeted vector and to tissue weight and then expressed as relative TU. Data shown are representative of two experiments, n = 5. One-way
ANOVA with Tukey’s multiple comparison test (GraphPad Prism 6) was used for data analysis.
D Quantification of the vector dose reaching orthotopic GBM in mice upon intravenous administration of 5 × 1010 TU of RGD4C/AAVP vector. The vector amount, in
tumors, was expressed as TU/g tumor tissue. Data shown are representative of two experiments, n = 5.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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mice that received the RGD4C/AAVP-Grp78-HSVtk plus GCV, the
Luc signals were reduced compared to the control non-targeted/
AAVP-Grp78-HSVtk plus GCV (Fig 4A–C), proving an inhibitory
effect on tumor growth and tumor viability. Treatment with TMZ
also resulted in tumor growth inhibition (Fig 4A–C). Remarkably, in
sharp contrast, at day 27 post-tumor cell implantation, expression of
the tumor Luc in mice receiving combination of RGD4C/AAVP-
Grp78-HSVtk/GCV and TMZ was dramatically reduced than the
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Figure 4. Therapeutic response of orthotopic U87 glioblastoma to combination of TMZ with RGD4C/AAVP-Grp78-HSVtk plus GCV.
A In vivo BLI of Luc expression for evaluation of tumor viability and tumor size of representative tumor-bearing mice from all experimental groups before initiation of
therapy (day 9 post-intracranial cell implantation) and at the end of treatments (day 27 post-intracranial cell implantation).
B Individual tumor Luc intensities before (filled circles) and after therapy (open circles), on days 9 and 27 post-cell implantation, respectively. Data shown are
representative of two experiments, n = 5.
C Average tumor Luc activity showing glioblastoma progression in each experimental group. Pre-treatment day 9 was set at 100%. Data shown are representative of
two experiments, n = 5.
D Survival benefit for tumor-bearing mice from all treatment groups. Data shown are representative of two experiments, n = 5. Statistical significance was determined
by Kaplan–Meier method (Kaplan–Meier survival fractions). Log-rank (Mantel–Cox) test was used.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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initial Luc signal recorded on day 9, showing not only a lack of
tumor growth but a substantial reduction in tumor size and tumor
viability (Fig 4A–C). Moreover, we evaluated efficacy on survival of
mice with intracranial U87 tumors. All the treatments—RGD4C/
AAVP-Grp78-HSVtk/GCV, TMZ alone, and combination of RGD4C/
AAVP-Grp78-HSVtk/GCV plus TMZ—increased the survival of
tumor-bearing mice (Fig 4D). Treatment with RGD4C/AAVP-Grp78-
HSVtk/GCV produced better survival for tumor-bearing mice when
compared to treatment with the non-targeted AAVP vector (Fig 4D).
Importantly, tumor-bearing mice receiving combination treatment
of RGD4C/AAVP-Grp78-HSVtk/GCV with TMZ showed the highest
survival benefit as compared to TMZ or RGD4C/AAVP-Grp78-
HSVtk/GCV alone.
Next, to check for post-treatment effects, tissues were snap
frozen at day 27 post-tumor cell implantation and sectioned. The
hematoxylin and eosin (H&E) staining of the brain sections revealed
a clear damage to tumors following systemic gene therapy with
RGD4C/AAVP-Grp78-HSVtk plus GCV compared to non-targeted/
AAVP-Grp78-HSVtk/GCV-treated tumors (Fig 5A). This anti-tumor
effect was comparable to that observed in tumors treated with
intraperitoneal TMZ. Remarkably, the H&E staining revealed exten-
sive and greater tumor destruction from a single systemic dose of
RGD4C/AAVP-Grp78-HSVtk/GCV plus TMZ treatment compared to
vector or TMZ alone (Fig 5A). Tumors were also analyzed for cell
proliferation by staining for the proliferation marker protein Ki67, a
protein strictly associated with cell proliferation, and revealed that
combination treatment of TMZ with RGD4C/AAVP-Grp78-HSVtk/
GCV generated the greatest reduction of cell proliferation compared
to tumors from mice that received monotherapies of TMZ alone or
RGD4C/AAVP-Grp78-HSVtk/GCV (Fig 5A). Moreover, immunofluo-
rescent analysis of CD31 for blood vessel staining (Fig 5B) showed
enlarged tumor blood vessels in mice that received the non-
targeted/AAVP-Grp78-HSVtk/GCV, while the tumor blood vessel
size was slightly reduced in mice treated with either RGD4C/AAVP-
Grp78-HSVtk/GCV or TMZ alone. In contrast, mice that had received
RGD4C/AAVP-Grp78-HSVtk/GCV plus TMZ showed normal blood
vessel size in the remaining tumor lesion (Fig 5B). We also exam-
ined the tumors for apoptosis by evaluating expression of the
caspase-3 which marks apoptotic cells, as the HSVtk/GCV is associ-
ated with apoptotic cell death. The data revealed that all treatments
induced apoptosis within the tumors compared to tumors from mice
that received the non-targeted control vector (Fig 5C). Interestingly,
combination treatment with TMZ and RGD4C/AAVP-Grp78-HSVtk/
GCV induced the highest level of apoptosis in glioblastoma (Fig 5C).
There was no weight loss noticed in the animals during the course
of treatment (Fig EV2A), and any weight loss, detected by the end
of the experiment, was solely related to the tumor burden.
To further confirm the vector safety, the toxicity of the RGD4C/
AAVP-Grp78-HSVtk was assessed in wild-type BALB/c mice adminis-
tered intravenously with increasing doses 2.5 × 109 TU (1 × 1011
TU/kg), 1 × 1010 TU (5 × 1011 TU/kg), or 5 × 1010 TU (2 × 1012
TU/kg) of the RGD4C/AAVP-Gp78-HSVtk (Fig EV3). These doses
were based on previous studies in mice and pet dogs (Paoloni et al,
2009), and on the clinical trial that performed intravenous injections
of the M13 phage, parent of AAVP, to cancer patients (Krag et al,
2006).
Next, we did not observe any abnormal changes in the healthy
tissues, no animal weight loss was noticed and the serum evaluation
of the lactate dehydrogenase (LDH), used as a biomarker for cellular
cytotoxicity and cytolysis, remained at normal levels (Fig EV3).
RGD4C/AAVP does transduce human primary GBM but not human
normal cells
We sought to evaluate efficacy of vector in human primary GBM
cells and performed several experiments by using two primary GBM
cells named HSJD-GBM-001 (Olaciregui NG and Carcaboso AM, in
preparation) and G26 (Pollard, 2013). GBM is a heterogeneous
tumor with low survival that has been, at least partly, caused by
glioma stem cells. These therapy-resistant GBM stem cell sub-
populations are a sub-set of slow-cycling cells endowed with stem
cell-like properties and able to resist the standard treatment and to
sustain the relapse. Therefore, we first analyzed the HSJD-GBM-001
spheres and G26 cells for the presence of stem cell-like properties,
since HSJD-GBM-001 are grown in serum-free medium, in vitro, to
generate spheroids for in vivo implantation into animals. We found
that HSJD-GBM-001 spheres express high levels of stem cell markers
(65.7% Sox-2+ cells, 62.7% of Nestin+ cells, and 93.6% CD133+
cells) proving that the HSJD-GBM-001 spheres contain high percent-
age of stem cells (Fig 6A). The G26 cells had 13.4% Sox-2+ cells,
45.7% of Nestin+ cells, and 43.5% CD133+ cells. These data con-
firm the heterogeneity of HSJD-GBM-001 spheres and G26 cells.
Next, we analyzed these GBM primary cells for expression of the
avb3 and avb5 integrin receptors. Immunofluorescence analyses
showed that the HSJD-GBM-001 primary cells express high levels of
the integrin subunits av, b3, and b5 (Fig 6B); G26 cells also express
these integrins but at lower levels than HSJD-GBM-001 spheres
(Fig 6B). Then, we showed that the RGD4C/AAVP-Luc vector effi-
ciently delivered gene expression to both HSJD-GBM-001 and G26
primary GBM, and gene delivery increased over time in a selective
manner as no gene expression was detected in cells treated with the
non-targeted vector, lacking the RGD4C ligand (Fig 6C). Gene deliv-
ery into HSJD-GBM-001 was higher than in G26 cells consistent with
the higher integrin expression in HSJD-GBM-001 cells. For instance,
at day 8, RGD4C/AAVP-Luc achieved Luc expression of ~ 570,000
RLU/lg protein in HSJD-GBM-001 cells compared to ~ 70,000 RLU/
lg protein in G26 cells (Fig 6C).
After demonstrating the potential of RGD4C/AAVP for gene
delivery to human glioblastoma cells through the RGD4C binding to
integrins, we sought to further assess the tumor cell selectivity of
vector and its safety for human healthy cells. Thus, we assembled a
panel of normal human primary cells from different histological
origins, such as primary glial cells (astrocytes) and chondrocytes,
and also included two types of human normal primary fibroblasts
from skin and lung since avb5 integrin is also found expressed on
normal fibroblasts. Firstly, we investigated expression of the inte-
grins avb3 and avb5 receptors. While the astrocytes showed very low
expression of av and b5, with barely detectable levels of b3,
immunostaining of the chondrocytes did not show any expression
of these integrins (Fig 7A). We also found that both primary fibro-
blasts have low levels of expression of av and b5 subunits, with
barely detectable b3 integrin (Fig 7A). Importantly, this low integrin
expression profile of normal cells did not translate into gene deliv-
ery by the RGD4C/AAVP-Luc vector alone or even in the presence
of TMZ (Fig 7B), as the luminescent signals were not different from
non-transduced cells at all time points. Consequently, unlike
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primary GBM, human normal cells show minimal or no expression
of these integrin receptors, and this integrin expression profile did
not permit any gene expression by the RGD4C/AAVP.
Systemic targeting of primary GBM by RGD4C/AAVP-Grp78-HSVtk
plus GCV inhibits tumor growth, and efficacy is enhanced by TMZ
To rule out the possibility that the observed anti-tumor effects on
orthotopic U87 GBM were specific to this GBM cell line, we
analyzed therapy efficacy on intracranial primary GBM derived from
the HSJD-GBM-001 spheres in nude mice, since they establish
intracranial GBM in immunodeficient mice with 100% take rate
(Olaciregui NG and Carcaboso AM, in preparation) and are hetero-
geneous with high levels of stem cell-like properties (Fig 6A). HSJD-
GBM-001-Luc cells stably expressing the Luc reporter gene were
grown in serum-free medium, in vitro, to generate spheres before
implantation into the brain of nude mice. Next, tumors were estab-
lished by intracranial GBM implantation as shown by the BLI of
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Figure 5. Histological analysis of intracranial U87-derived glioblastoma after therapy.
A Hematoxylin and eosin staining (H&E) and immunostaining for the proliferation marker protein Ki67 of representative tumor sections from all experimental groups,
Scale bars, 200 lm for H&E and 100 lm for Ki67. The low-magnification inserts represent negative controls with the secondary antibody alone on serial sections
used for both Ki67 and caspase-3 immunostainings.
B Blood vessel staining with CD31 (red). DAPI staining of the sections is shown in blue. Scale bar, 200 lm.
C Tumor immunostaining for apoptosis using an anti-caspase-3 antibody. Scale bar, 100 lm.
Data information: T, tumor; B, brain.
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Figure 6. Characterization of the human primary GBM and then analysis of targeted gene delivery.
A Fluorescence-activated cell sorting (FACS) analysis with antibodies against Sox-2, Nestin, and CD133 stem cell markers.
B Immunofluorescent staining for av, b3, or b5 integrins in primary HSJD-GBM-001 and G26 GBM cells. Scale bars, 80 lm for HSJD-GBM-001 and 100 lm for G26.
C Targeted transduction of HSJD-GBM-001 and G26 cells, over a time course, by RGD4C/AAVP-Luc. Non-targeted/AAVP-Luc was used as negative control. Results
represent RLU/1 lg protein of triplicate wells. Data shown are representative of two experiments, n = 3. Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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Figure 7. Integrin expression in human primary normal cells and then analysis of targeted gene delivery.
A Immunofluorescent staining for av, b3, or b5 integrins in human normal astrocytes, chondrocytes, skin, and lung fibroblasts. Scale bars, 160 lm for chondrocytes and
80 lm for all other cells.
B Treatment of human primary normal cells with RGD4C/AAVP-Luc vector, alone or in the presence of TMZ. Non-targeted/AAVP-Luc was used as negative control.
Results represent RLU/1 lg protein. Data shown are representative of two experiments, n = 3.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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Luc; subsequently, the RGD4C/AAVP-Grp78-HSVtk or control
vectors were intravenously injected into tumor-bearing nude mice.
Consistent with U87 xenografts, daily treatment with GCV and TMZ
was initiated at day 4 post-vector injection and continued for
6 days. At day 19 post-treatment initiation, BLI imaging of Luc
showed that tumors from mice treated with the targeted RGD4C/
AAVP-Grp78-HSVtk and GCV had lower Luc signals and were
smaller compared to tumors treated with the control non-targeted
vector and GCV (Fig 8A). Similar effects were also observed in mice
receiving TMZ treatment (Fig 8A). Interestingly, barely detectable
tumor Luc signals were observed in mice treated with combination
of TMZ with RGD4C/AAVP-Grp78-HSVtk plus GCV compared to
mice administered with RGD4C/AAVP-Grp78-HSVtk plus GCV or
TMZ alone (Fig 8A). To support these imaging findings, we investi-
gated whether the observed anti-tumor effects against primary GBM
would translate into overall survival benefit, under the same experi-
mental protocol above. The results showed a survival benefit in the
mice treated with the RGD4C/AAVP-Grp78-HSVtk and GCV
compared to the non-targeted vector/GCV-treated mice (Fig 8B, half
the animals survived 54 days versus 47 days, respectively). Survival
was also improved in TMZ-treated mice (Fig 8B, half the animals
survived 66 days). Importantly, the best survival benefit was
obtained in tumor-bearing mice treated with the combination
therapy of TMZ with RGD4C/AAVP-Grp78-HSVtk and GCV, as
compared to TMZ or vector alone (half the animals survived
72 days versus 66 and 54, respectively). Additionally, while there
was no animal survival at day 54 post-cell implantation in mice
treated with the control non-targeted vector, mice treated with
combination RGD4C/AAVP-Grp78-HSVtk/GCV and TMZ could
survive beyond day 90 post-cell implantation compared to days 66
and 73 for RGD4C/AAVP-Grp78-HSVtk/GCV and TMZ-treated mice,
respectively (Fig 8B).
Moreover, we analyzed post-treatment effects and carried out
detailed histopathological analysis of tumors recovered 12 days
after therapy. Specifically, H&E staining revealed tumor destruction
caused by the single systemic dose of RGD-4C/AAVP-HSVtk plus
GCV, as well as by TMZ treatment, when compared to control
tumors from mice injected with the non-targeted vector and GCV
(Fig 8C). Interestingly, combination treatment further enhanced
destruction of the central area of the tumor compared to each treat-
ment alone (Fig 8C). Moreover, these findings were consistent with
the staining for the proliferation marker protein Ki67, showing the
lowest level of cell proliferation observed in tumors from mice
treated with combination of TMZ and RGD4C/AAVP-Grp78-HSVtk/
GCV, compared to each treatment alone (Fig 8C). Immunostaining
for caspase-3 showed that apoptosis has become clearly visible in
tumors from mice treated with combination of TMZ and RGD4C/
AAVP-Grp78-HSVtk plus GCV (Fig 8C). Apoptosis was also induced
in tumors from mice treated with either RGD4C/AAVP-Grp78-HSVtk
plus GCV or TMZ. Finally, immunostaining of HSJD-GBM-001
tumors for the CD133+ stem cell marker showed that tumors recov-
ered from the control group are rich in stem cells proving the
heterogeneity of the established intracranial tumors (Fig 8D). Inter-
estingly, we detected clear reduction of cancer stem cells following
treatment with RGD4C/AAVP-Grp78-HSVtk plus GCV, compared to
TMZ treatment (Fig 8D). Notably, combination treatment with
RGD4C/AAVP-Grp78-HSVtk plus GCV and TMZ resulted in marked
suppression of the CD133+ cells (Fig 8D).
There was no apparent toxicity as the mice did not lose signifi-
cant weight during the course of the therapy (Fig EV2B), and the
control organs removed from tumor-bearing mice treated by the
same experimental protocol revealed no histopathologic abnormali-
ties (Fig EV2C). Additionally, immunostaining against the RGD4C/
AAVP-Grp78-HSVtk vector, using an antibody against the vector
capsid, did not reveal any vector presence in the normal tissues
(liver, kidney, heart, and lung) recovered after therapy (Fig EV2D).
Importantly, tumors were stained positive for the vector upon
administration of RGD4C/AAVP-Grp78-HSVtk or a combination of
RGD4C/AAV-Grp78-HSVtk and TMZ (Fig EV2D).
Targeted systemic gene therapy with RGD4C/AAVP-Grp78-HSVtk
plus GCV inhibits tumor growth of orthotopic GBM in
immunocompetent mice, and efficacy is boosted by TMZ
To rule out the possibility that the anti-tumor effects of this treat-
ment regimen were specific to immunosuppressed mice, or either
species or xenograft specific, we evaluated efficacy of the RGD4C/
AAVP-Grp78-HSVtk on a standard mouse GBM model. We chose
an isogenic tumor in which GL261 mouse glioblastoma cells are
implanted intracranially to induce rapid growth of tumors in
immunocompetent C57BL/6J mice. The GL261 tumor is the most
recognized murine GBM model that has been extensively used for
preclinical testing of therapeutic approaches for GBM (Oh et al,
2014). First, we confirmed that the GL261 cells express high levels
of the integrin subunits av, b3, and b5 receptors that mediate cell
transduction by the RGD4C/AAVP vector (Fig 9A). Next, to estab-
lish orthotopic GBM for therapy experiments, we used the GL261-
Luc labeled with the Luc gene to allow bioluminescent imaging
(BLI). Following brain tumor detection by BLI, tumor-bearing
mice were injected intravenously with targeted RGD4C/AAVP-
Grp78-HSVtk or control non-targeted vectors (5 × 1010 TU/mouse).
Daily treatment with GCV and TMZ was initiated at day 4 post-
vector injection and lasted for 5 days. Moreover, this treatment
regimen was repeated three times to complete a total of three
serial vector administrations, as we previously reported efficacy of
repeated administrations of RGD4C/AAVP in immunocompetent
BALB/c mice and immunocompetent pet dogs with natural tumors
(Hajitou et al, 2006; Paoloni et al, 2009). At day 34 post-treatment
initiation, BLI imaging revealed that the group of tumor-bearing
mice treated with the targeted RGD4C/AAVP-Grp78-HSVtk plus
GCV had smaller tumors with lower viability as shown by the
total Luc signals in tumors, compared to the large size and highly
viable tumors from mice receiving the control non-targeted vector
and GCV (Fig 9B and C). Comparable effects were also observed
in mice treated with TMZ (Fig 9B and C). Remarkably, no tumor
Luc signals were observed in mice treated with combination
of TMZ with RGD4C/AAVP-Grp78-HSVtk plus GCV, indicating
striking tumor suppression by this combination treatment (Fig 9B
and C).
Moreover, we investigated whether the repeated treatment regi-
men resulted in extended overall survival. There was a survival
benefit following administrations of RGD4C/AAVP-Grp78-HSVtk
and GCV compared to the non-targeted vector/GCV; survival was
also improved in TMZ-treated group (Fig 9D). For instance, while
there was no animal survival at day 38 post-tumor cell implantation
in the control group, mice treated with RGD4C/AAVP-Grp78-HSVtk/
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Figure 8. Targeted systemic gene therapy against orthotopic primary HSJD-GBM-001 with RGD4C/AAVP-Grp78-HSVtk plus GCV and combination with TMZ.
A BLI of luciferase of representative tumor-bearing mice from all experimental groups at day 19 post-therapy initiation.
B Survival benefit for tumor-bearing mice from all treatment groups. Data shown are representative of two experiments, n = 6. Statistical significance was determined
by Kaplan–Meier method (Kaplan–Meier survival fractions). Log-rank (Mantel–Cox) test was used.
C H&E staining, Ki67 immunostaining, and evaluation of apoptosis in tumors by using an anti-caspase-3 antibody staining of representative tumor sections from all
experimental groups. The low-magnification inserts represent negative controls with the secondary antibody alone on serial sections used for both Ki67 and caspase-
3 immunostainings. Arrow points to apoptotic cells. Scale bars, 100 lm.
D Immunostaining of tumors with an antibody against CD133. Scale bars, 100 lm.
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GCV or TMZ survived beyond day 62 (Fig 9D). Remarkably, 80% of
mice treated with combination RGD4C/AAVP-Grp78-HSVtk/GCV
and TMZ could survive past day 62 post-cell implantation (Fig 9D).
There was no noticeable toxicity as there was no weight loss
noted in the animals during the course of therapy (Fig 9E), and any
weight loss detected by the end of the experiment was exclusively
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Figure 9. RGD4C/AAVP-Grp78-HSVtk plus GCV gene therapy and combination with TMZ against orthotopic murine GL261 GBM.
A Immunostaining analysis for av, b3, or b5 integrins in GL261 cells. Scale bar, 50 lm.
B BLI of Luc of representative tumor-bearing mice from all experimental groups at day 34 post-treatment.
C Total tumor Luc intensities in each experimental group before treatment, on day 10 post-cell implantation, and after therapy, on day 34 post-cell implantation. Data
shown are representative of two experiments, n = 6. Data analysis was done by two-way ANOVA and Bonferroni’s multiple comparison test.
D Survival benefit for tumor-bearing mice from all treatment groups. Data shown are representative of two experiments, n = 6. Statistical significance was determined
by Kaplan–Meier method (Kaplan–Meier survival fractions). Log-rank (Mantel–Cox) test was used.
E Weights of C57BL/6J mice bearing intracranial GL261 tumors, from all experimental groups, before and after treatment. Data shown are representative of two
experiments, n = 6.
Data information: Data are expressed as mean  SEM.
Source data are available online for this figure.
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associated with the intracranial tumor burden. Moreover, H&E stain-
ing of healthy tissues did not reveal any tissue damage or abnormal-
ities following repeated treatment with the combination regimen
(Fig EV4).
Discussion
In this study, we combined the chemotherapeutic drug TMZ with
RGD4C/AAVP-Grp78-mediated systemic gene therapy, delivered
intravenously in mice, against intracranial human models of
glioblastoma. We showed that RGD4C/AAVP delivers gene expres-
sion in vitro in a diverse panel of human GBM cell lines, primary
GBM and GBM stem cells in a targeted and efficient manner, medi-
ated through binding of the RGD4C to avb3 integrin, as all tumor cells
and GBM stem cells tested in this study express this integrin and no
gene delivery was obtained with vector lacking the RGD4C ligand.
The av, b3, and b5 subunits form integrin heterodimers such as avb3
that can bind the RGD4C ligand and internalize the RGD4C/AAVP,
and the avb5 heterodimer that can also bind RGD4C, but to a lesser
extent than avb3. Targeting avb3 integrin in human GBM with RGD4C
was performed in patients (Reardon et al, 2008). Previous studies
reported that avb3 integrin can be expressed in up to 55% of human
glioblastoma, depending on the tumor grade (Schnell et al, 2008;
Schittenhelm et al, 2013). The avb3 expression was significantly
higher in human GBMs than in low-grade gliomas and was seen on
both activated endothelial cells and glial tumor cells existing within
glioblastomas (Schnell et al, 2008; Schittenhelm et al, 2013). In
contrast, avb3 expression is barely detectable on normal human
endothelial cells (Koch, 2000; Pap et al, 2000; Van De Wiele et al,
2002; Kumar, 2003; Gamble et al, 2010) and is also not expressed on
glia or neurons in normal adult cortex and cerebral white matter
(Gladson & Cheresh, 1991). Moreover, in the present study, we con-
firmed that the minimal expression of these integrin heterodimers in
normal human primary cells including glial cells did not lead to gene
delivery by the targeted RGD4C/AAVP-Grp78 vector.
Then, we found that TMZ stimulates gene expression from the
Grp78 promoter, but not from the CMV promoter, in GBM cells by
activating the UPR stress pathway that ultimately results in the stim-
ulation of Grp78 promoter. TMZ-induced expression and activation
of the endogenous GRP78 promoter have been reported in human
glioblastoma (Pyrko et al, 2007; Virrey et al, 2008), and induction
of Grp78 has been reported in various cancer therapies, including
chemotherapy (Li & Lee, 2006; Lee, 2007; Pyrko et al, 2007; Virrey
et al, 2008). Grp78 is a stress-inducible gene that encodes for a
potent anti-apoptotic protein, which plays a critical role in tumor
survival and resistance to therapy (Yu et al, 1999; Lee, 2001; Li &
Lee, 2006; Daneshmand et al, 2007; Nagelkerke et al, 2014). In
addition to TMZ, other therapeutic approaches can also be used to
induce the Grp78 promoter, e.g., radiation therapy (Sun et al, 2017)
and other chemotherapeutic drugs used for brain tumor treatment
such as cisplatin (Mandic et al, 2003). Moreover, we demonstrated
that safe anti-cancer agents such as curcumin from natural sources,
known for its ability to cross the BBB (Klinger & Mittal, 2016), have
the potential to induce the RGD4C/AAVP-Grp78 vector promoter in
human primary gliomas, consistent with previous studies reporting
induction of the Grp78 in cancer cells, by curcumin, through the
UPR pathway (Kim et al, 2016).
In the present study, combination of TMZ with vector carrying
the HSVtk gene increased the cell death of GBM cell lines in vitro but
the effect of combining TMZ with RGD4C/AAVP-Grp78 was more
pronounced than of TMZ combined with RGD4C/AAVP-CMV, which
could be explained by TMZ induction of gene expression from the
Grp78 promoter. The difference between RGD4C/AAVP-Grp78/TMZ
and RGD4C/AAVP-CMV/TMZ combinations was less pronounced in
cell killing than in Luc gene expression analyses. However, it is
important to note that the HSVtk/GCV approach induces a bystander
effect (Trepel et al, 2009), which can result in increased cell killing
by the RGD4C/AAVP-CMV. Thus, the cell killing results are partially
proportional to the transduction efficiency.
Some of our results merit further discussion. Although the
SNB19 cells exhibited a slower activation of the Grp78 promoter by
TMZ, these cells showed the best response to TMZ addition as
compared to LN229 and U87 cell lines. However, these cells also
showed the most response of Grp78 promoter to addition of GCV.
Therefore, it is possible that the highest response of SNB19 cells to
TMZ plus GCV combination might, at least in part, be associated
with the elevated response of Grp78 promoter, in these cells, to GCV
treatment. We previously reported that HSVtk/GCV therapy upregu-
lates Grp78 and transgene expression in glioma cells via the
conserved UPR signaling cascade (Kia et al, 2012). On the other
hand, cell death was measured at day 4 post-GCV addition, at which
time point the HSVtk/GCV bystander effect might take over resulting
in increased cell killing by the RGD4C/AAVP-Grp78-HSVtk and
GCV. Thus, the cell killing data should not be completely propor-
tional to the levels of induction of HSVtk expression. We have also
confirmed that the cells express connexin-26 (Fig EV5); connexins
are proteins associated with the bystander effect as they compose
the channels of the GJIC through which toxic phosphorylated GCV
is exchanged between cells.
In vivo, we found that systemic combination of TMZ with a
single intravenous dose of RGD4C/AAVP-Grp78-HSVtk and GCV
yielded synergistic and more pronounced anti-tumor effect than
gene therapy or chemotherapy alone, both against orthotopic U87-
derived xenografts and human primary GBM. Various factors could
contribute to this striking anti-tumor effect. Firstly, an increase in
TMZ-induced HSVtk expression from RGD4C/AAVP-Grp78-HSVtk
by TMZ could reach high therapeutic HSVtk levels and subsequently
increase the effect of targeted gene therapy. Secondly, synergy
between HSVtk and TMZ against human glioblastoma has been
reported (Rainov et al, 2001). Finally, a likely advantage of using
RGD4C ligand is that it can target both the accessible tumor vascula-
ture and the tumor cells giving the vector a dual mechanism for
inducing tumor death. Previous studies reported that Grp78 was
induced by TMZ in both tumor cells and associated vasculature in
GBM (Pyrko et al, 2007; Virrey et al, 2008). Our findings demon-
strated that RGD4C/AAVP-Grp78 is localized in both compartments
of intracranial human GBM in mice. A notable finding from the
in vivo studies is the ability of RGD4C/AAVP-Grp78-HSVtk vector
plus GCV to produce a destruction of the GBM stem cells in vivo
within the tumors and its enhancement in the presence of TMZ.
These data are supported by our in vitro studies demonstrating effi-
cient transduction of primary GBM stem cells by the RGD4C/AAVP
vector. These findings are encouraging since GBM are heteroge-
neous tumors containing a sub-population of cells with stem cell-
like properties that are resistant to standard treatment. Moreover,
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developing a selective viral vector for GBM stem cells has been chal-
lenging (Dey et al, 2011); the RGD4C/AAVP vector holds promise
for targeted delivery of therapeutic nucleic acids to GBM stem cells.
Immunostaining experiments revealed that RGD4C/AAVP-Grp78-
HSVtk accumulates in intracranial tumors, derived both from the U87
and primary GBM cells, following intravenous administration. In
contrast, no presence of vector was observed in the surrounding
healthy brain and other vital normal tissues, consistent with previous
studies. We and others previously reported the ability of RGD4C/
AAVP to home selectively to tumors in preclinical models in mice and
rats as well as in natural tumors in large animal models, while spar-
ing the normal tissues, and subsequently deliver gene expression to
tumors selectively without any detectable gene expression in the
healthy tissues (Hajitou et al, 2006, 2007, 2008; Paoloni et al, 2009;
Tandle et al, 2009; Kia et al, 2012; Przystal et al, 2013; Yuan et al,
2013; Dobroff et al, 2016; Smith et al, 2016). Herein, our findings
revealed that the selective tumor homing is consistent with av integrin
expression in the tumors but not in healthy brain. Some of these
results merit further discussion. The ability of phage to cross the BBB
was described as early as 1943 by Dubos et al (Dubos et al, 1943) in
an investigation to treat meningitis in mice with intraperitoneal phage
mixtures. In 2002, Frenkel and Solomon (Frenkel & Solomon, 2002)
reported that intranasal administration in mice resulted in accumula-
tion of M13 phage, parent of AAVP, in the brain. Moreover, an
elegant study showed the ability of a glioma-binding M13 phage to
cross the BBB in intracranial human gliomas in mice and achieve
selective tumor homing upon intravenous administration (Ho et al,
2004, 2010). There is no clear mechanism for RGD4C/integrin-guided
AAVP penetration into brain tumors. Our hypothesis is that the
RGD4C/AAVP diffusion within the tumors, dual targeting of both the
tumor vasculature and tumor cells and induction of Grp78 promoter
by TMZ could account for the therapeutic potential of RGD4C/AAVP-
Grp78-HSVtk/GCV and TMZ combination against GBM.
In conclusion, these studies might be able to alter clinical use of
TMZ chemotherapy of GBM but may also influence intravenous
targeted gene therapy with RGD4C/AAVP-Grp78 against GBM.
Combinatorial treatment regimens more often constitute a success-
ful approach to overcome resistance to therapies, which is a hall-
mark of GBM. Beyond that, potential synergistic interactions
between the combined TMZ and RGD4C/AAVP-Grp78-HSVtk/GCV
should permit possible dose reductions of TMZ, both to a less toxic
and to a less costly degree. Cells transduced by RGD4C/AAVP-
Grp78-HSVtk unintentionally enhance their own death upon TMZ
dose/duration regimen treatment by activating the UPR stress path-
way and ultimately HSVtk expression from the RGD4C/AAVP-
Grp78-HSVtk. Phage-guided anti-cancer therapy can enter clinical
trials in cancer patients as bacteriophages have long been safely
administered to humans, from their antibacterial use during the pre-
antibiotic era (Asavarut & Hajitou, 2014) to the Food and Drug
Administration approval of certain phage preparations as antibacte-
rial food additives (Lang, 2006). In this study, we also confirmed
the anti-tumor effect of this treatment regimen against GBM estab-
lished in immunocompetent mice by applying three serial vector
administrations that were safely accomplished without any
unwanted adverse reactions. The M13 phage, parent of RGD4C/
AAVP-Grp78 vector, was well reported for its immunogenicity
(Trepel et al, 2001). Importantly however, we and collabora-
tors have established that repeated administrations of RGD4C/
AAVP-HSVtk proved safe and efficient to inhibit tumor growth in
wild-type animals and subsequently improve their survival (Hajitou
et al, 2006; Paoloni et al, 2009). Moreover, clinical trials in cancer
patients showed that serial intravenous phage library administra-
tion, based on the M13 phage, can be accomplished without major
untoward clinical effects (Arap et al, 2002; Krag et al, 2006) despite
the presence of anti-M13 phage IgGs. Phage-based particles are
known to be immunogenic, but this feature can be modulated
through targeting itself (Trepel et al, 2001).
Materials and Methods
Cell culture
LN229, U87, and SNB19 cell lines were purchased from American
Type Culture Collection (ATCC). GL261 cells were obtained from
The Leibniz Institute DSMZ, Germany. Primary human skin and
lung fibroblasts were a gift from Dr. David Abraham, Royal Free
Hospital, United Kingdom. Primary human chondrocytes were a gift
from Dr. Peraphan Pothacharoen, Chiang Mai University, Thailand,
and primary astrocytes were obtained from the ATCC. All these cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), except astrocytes
that were grown in the Astrocyte medium supplemented with Astro-
cyte supplements.
Primary human GBM HSJD-GBM-001 and primary pediatric
human glioma were established at the Hospital Sant Joan de Deu,
Barcelona, Spain, and were grown in tumor stem medium (TSM;
50% Neurobasal-A Medium (1×), 50% DMEM/F12 (1×), 1% HEPES
buffer solution (1 M), 1% sodium pyruvate MEM (100 mM), 1%
MEM Non-Essential Amino Acids solution 10 mM (100×), 1%
GlutaMAX supplement, 1% Antibiotic-Antimycotic (100×), and 10%
FBS).
Primary Human GBM G26 (provided by Pr. Steven Pollard from
the Edinburgh Brain Cancer, University of Edinburgh, Scotland) was
maintained in serum-free cultures on laminin, using neural stem
(NS) cell media supplemented with EGF and FGF-2 to final concen-
tration of 10 ng/ml as reported (Pollard, 2013).
GCV was used at 10 lmol/l, while TMZ was applied at various
concentrations depending on the experiment and the cell type, as
indicated in the manuscript, and renewed daily. Curcumin was
added to cells at day 3 post-vector transduction and gene expression
measured at day 6.
Expression of the luciferase, Luc, reporter gene in vitro was
determined by a luciferase enzymatic assay using The Promega
Steady-glo Luciferase Assay Kit according to the manufacturer’s
instructions and then quantified with a Promega Glomax microplate
reader.
Transduction of cells by AAVP vectors was performed in serum-
free media as reported (Hajitou et al, 2007).
Production, purification, and titration of AAVP vectors
AAVP vectors were generated as previously reported (Hajitou et al,
2006; Kia et al, 2012) by inserting a recombinant rAAV2 genome
containing the reporter or therapeutic genes into the fUSE5 plasmid
derived from the filamentous fd-tet bacteriophage. AAVP viral
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particles were produced and purified from the culture supernatant
of Escherichia coli K91kan host bacteria, then sterile-filtered through
0.45-lM filters (Hajitou et al, 2006). The AAVP titer was calculated
by infecting K91 host bacteria and expressed as bacterial transduc-
ing units (TU/ll) as reported (Hajitou et al, 2006, 2007).
Integrin staining in cells
Tumor and normal cells were stained for av, b3, and b5 integrins on
poly-D-lysine-coated coverslips in 12-well plates as previously
reported (Stoneham et al, 2012). Cells were viewed, and images
were taken using a Nikon Eclipse TE2000-S fluorescence microscope.
Western blot
Whole-cell lysates were prepared in radioimmunoprecipitation assay
buffer (RIPA) and subjected to immunoblot. We used goat anti-Grp78
(C-20, 1:400), mouse anti-GAPDH (6C5, 1:1,000), mouse anti-ATF6
(IMG-273, 5 lg/ml) from Imgenex, USA, and rabbit-anti phosphor-
eIF2a (1:1,000) from Cell Signaling. We also used a mouse anti-
connexin 26 antibody (1:1,000). Each immunoblot was done three
times, quantified by ImageJ software, and normalized to GAPDH.
XBP1 splicing measurement
To detect unspliced and spliced forms of the XBP1, semi-quantita-
tive RT–PCR was performed as we previously described (Kia et al,
2012) by using the forward TTACGAGAGAAAACTCATGGCC and
reverse GGGTCCAAGTTGTCCAGAATGC primers.
MitoSOXTM Red staining for Fluorescence-Activated Cell Sorting
(FACS) and Sulforhodamine B (SRB) assay
MitoSOXTM Red reagent is a live-cell dye that is rapidly and selec-
tively targeted to the mitochondria to stain the ROS/superoxide.
MitoSOXTM Red staining was performed according to the manufac-
turer’s instructions. The SRB assay was carried out as previously
reported (Vichai & Kirtikara, 2006).
Animal models and anti-tumor therapy
Human intracranial tumors were established in immunodeficient
mice by using the U87 cell line or HSJD-GBM-001 spheres, while the
GL261 cells were implanted intracranial into immunocompetent
C57BL/6J mice to generate murine GBM. These cells were first
labeled with the Luc reporter gene by using a lentiviral vector (Sys-
tem Biosciences) to generate the U87-Luc, HSJD-GBM-001-Luc, and
GL261-Luc cells. Then, a total of 2.5 × 105 U87-Luc, 5 × 105 HSJD-
GBM-001-Luc, or 1.0 × 105 GL261-Luc cells were implanted into the
brain of mice. Tumor-bearing mice were intravenously administered
through the tail vein with targeted or control non-targeted vectors
carrying the HSVtk at a dose of 5 × 1010 TU vector/mouse (Hajitou
et al, 2006, 2007).
In therapy experiments, GCV (70 mg/kg/day) and TMZ
(30 mg/kg/day) were administered intraperitoneally. Tumor
growth was monitored two to three times a week by BLI of Luc
using the In Vivo Imaging System (IVIS 100; Caliper Life Sciences).
A region of interest was defined manually over the tumors for
measuring signal intensities recorded as total photon counts per
second per cm2 (photons/sec/cm2/sr; Hajitou et al, 2006, 2007).
At the end of therapy, mice were killed by terminal perfusion
through the heart, and then, the tumors and normal tissues were
harvested.
In tumor homing experiments, mice were perfused at 18 h post-
vector administration, and then, the tumors and control organs were
removed and weighted. Tissues were then ground with a glass
Dounce homogenizer, suspended in 1 ml of DMEM containing protei-
nase inhibitors (1 mM phenylmethylsulfonyl fluoride (PMSF),
20 lg/ml aprotinin, and 1 lg/ml leupeptin), vortexed, and washed
three times with DMEM. To quantify vectors, tissue homogenates
were incubated with 1 ml of host bacteria (log phase E. coli K91kan;
OD600  2). Aliquots of the bacterial culture were plated onto Luria–
Bertani agar plates containing 40 lg/ml tetracycline and 100 lg/ml
of kanamycin. Plates were incubated overnight at 37°C, followed by
colony counting, to determine the amount of functional RGD4C/
AAVP as TU and subsequently evaluate the vector dose that reaches
the whole tumor versus the healthy tissues upon intravenous admin-
istration of 5 × 1010 TU of RGD4C/AAVP particles. Vector accumula-
tion in tumors was expressed as TU/g of tumor tissue.
In the toxicity study in wild-type female BALB/c mice, quantita-
tive evaluation of the LDH was done by using the CytoTox 96
colorimetric Cytotoxicity Assay (Promega).
We have used 5–6 mice per group and repeated the experiments
twice. Mice nude female and immunocompetent C57BL/6J or
BALB/c female mice, adult 5–7 weeks, were purchased from
Charles River, United Kingdom. Athymic nude mice are more prone
to infection by opportunistic pathogens and were thus housed
behind appropriate barrier housing; irradiated diet and bedding
were also provided to reduce the risk of infection. Experiments
involving living mice were carried out according to the Institutional
and Home Office Guidelines, and under a granted Home Office-
issued project license. The project license was first reviewed and
approved by the Animal Welfare and Ethical Review Body (AWERB
committee) at Imperial College London, before its final review and
approval by the Home Office.
Immunohistochemistry
Tumor vascularization, phage immunodetection, and integrin
expression were assessed on frozen sections by using antibodies
against CD31 (vascular marker), phage, and av integrin. Frozen
sections (8 lm) were washed with 1×PBS (phosphate buffer saline)
and 0.3% Triton X-100 (PBS-Tween, or PBS-T) and then blocked
with 10% BSA in 0.1% PBS-T for 60 min at RT. Slides were incu-
bated for 48 h at 4°C with rabbit anti-human av integrin (1:200) or
both with rabbit anti-fd phage (1:500) and rat anti-mouse CD31
(1:50) antibodies diluted in 0.1% PBS-T with 1% BSA. Next,
sections were washed and stained for 1 h at room temperature with
the secondary antibodies AlexaFluor 488 goat anti-rabbit (1:500)
and AlexaFluor 594 donkey anti-rat (1:500). Immunolabeling for the
proliferation marker protein Ki67 was performed using a polyclonal
primary rabbit antibody (1:400, Abcam). Analysis of apoptosis was
done on frozen sections by immunostaining with an anti-caspase-3
rabbit antibody (1:1,000, Cell Signaling) that also detects the
cleaved caspase-3. Immunostaining for caspase-3 was performed
similar to Ki67 using a secondary biotinylated anti-rabbit antibody
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(1:400). Both Ki67 and caspase-3 immunostainings were carried out
on tumor serial sections, in similar tumor areas in each experiment,
in order to test whether tumors are simultaneously undergoing
reduction of proliferation and apoptosis. Staining for the stem cell
marker CD133 in tumors was performed using an anti-CD133 mono-
clonal antibody (Miltenyi Biotec).
Stem cell marker staining for FACS
We used primary monoclonal antibodies for Sox-2 (1:50, Biole-
gend), for CD133 (1:50, Miltenyi Biotec), and for Nestin (5 lg, R&D
Systems).
Statistical analysis
P values were generated by using either one-way ANOVA with
Tukey’s multiple comparison test (GraphPad Prism 6) or two-way
ANOVA and Bonferroni’s multiple comparison test, two-way
ANOVA with Bonferroni correction (GraphPad Prism 6), and two-
way ANOVA with Tukey’s multiple comparison test (GraphPad
Prism 6). In animal survival experiments, Kaplan–Meier method
(Kaplan–Meier survival fractions) was used to generate P values
and calculate the Log-rank (Mantel–Cox). Error bars represent stan-
dard error of the mean (SEM).
In vitro experiments were designed to ensure 5% significance
level and a minimum of 80% power. Experiments were performed
in triplicate and repeated, at least twice, increasing the total number
of samples to n = 6, which is sufficient for a statistical power above
80%.
For animal experimentation, we used a randomized experimental
design and blinding was also applied throughout the animal studies.
Briefly, following tumor detection in mice by BLI of Luc, tumor-
bearing mice were randomly assigned to experimental groups. Imag-
ing of tumor-bearing mice was done, cage by cage, blindingly and
by fixing the same parameters for all the cages. Histopathological
analyses were also performed blindly. We have used 5–6 mice per
group and repeated the experiments twice.
Expanded View for this article is available online.
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